Core trials

Trials open to recruitment

IDEA-FAST

For patients with chronic diseases such as neurodegenerative disorders and immune-mediated inflammatory diseases, a key attribute for any successful therapeutic intervention is its ability to improve the patients’ activities of daily living…

SINAPPS2

Psychosis and schizophrenia are caused by factors associated with excess dopamine and abnormally low N-methyl D-aspartate receptor (NMDAR) functioning. There is increasing evidence for the role of inflammation in these disorders. We propose that…

The PHOSPHATE Trial

Binding of intestinal phosphate in patients with KF has been practiced for more than half a century. Today, 88% of UK dialysis patients require binders to achieve treatment targets. Although dialysis is a life-sustaining therapy, the death rate…

The SIMPLIFIED Registry Trial

In the United Kingdom, nearly 30,000 people receive regular dialysis and 6,000 new patients start dialysis each year. Although this is a life-saving treatment, dialysis-requiring renal failure carries a worse prognosis than most malignancies,…

TURING

Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) are auto-immune renal diseases that present with a common clinical phenotype, the nephrotic syndrome (NS), characterised by heavy proteinuria and debilitating oedema. When…